MediPharm Labs Launches LABS CANNABIS, A New and Innovative Family of Health and Wellness Products

BARRIE, Ontario, Oct. 20, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the launch of its new “LABS Cannabis” family of health and wellness products. Specially designed and formulated for theContinue reading “MediPharm Labs Launches LABS CANNABIS, A New and Innovative Family of Health and Wellness Products”

MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life

Clinical trial will evaluate the effectiveness of MediPharm Labs proprietary GMP cannabis-derived formulations and medical products and expand MediPharm Labs owned IP In the United States, 37 million or more than 1 in 7 adults, are estimated to have chronic kidney disease (CKD) and Worldwide, approximately 1 in 10 people suffer from kidney disease accordingContinue reading “MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life”

European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs

A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large pharmaceutical company commercializing medical cannabis products Partnership validates MediPharm Labs’ GMP pharmaceutical-quality cannabis production and, combined with STADA’s 125-year heritage and experienced marketing and sales platform, will meet the growing demand of the medical cannabis market,Continue reading “European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs”

MediPharm Labs Secures 100% Ownership of its Australia Subsidiary, Poised for New Wave of Global Medicinal Cannabis Growth

TORONTO, Sept. 28, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has entered into a share sale and purchase agreement (the “Buyout Agreement”) with its local Australian partner to acquire its 20% ownershipContinue reading “MediPharm Labs Secures 100% Ownership of its Australia Subsidiary, Poised for New Wave of Global Medicinal Cannabis Growth”

MediPharm Labs Enters Brazil – Latin America’s Largest Medical Cannabis Market in Partnership with XLR8 Brazil

 — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly owned subsidiary MediPharm Labs Inc. will supply premium, GMP-certified formulated cannabis oil to XLR8 BRAZIL (“XLR8”), a Rio de Janeiro based value-added distributor serving Brazil, Latin America’sContinue reading “MediPharm Labs Enters Brazil – Latin America’s Largest Medical Cannabis Market in Partnership with XLR8 Brazil”

MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru

— MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly owned subsidiary MediPharm Labs Inc. will supply premium, formulated cannabis oil to Cann Farm Peru S.A.C., a Lima-based producer and distributor serving Peruvian and other markets inContinue reading “MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru”

MediPharm Labs and Georgian College Complete First Research and Innovation Collaboration Driving Data and Analytics

Ontario, – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has completed work associated with a Research and Innovation Collaboration Agreement with Georgian College for a Data and Analytics Insights project. This four-month applied research projectContinue reading “MediPharm Labs and Georgian College Complete First Research and Innovation Collaboration Driving Data and Analytics”

MediPharm Labs Enters Denmark Medical Cannabis Market, Secures New White-Label Supply Customers

— MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it will supply cannabis concentrate products in Denmark to two new medical cannabis customers under two separate white-label agreements.  These customers will be serviced by both GMP approvedContinue reading “MediPharm Labs Enters Denmark Medical Cannabis Market, Secures New White-Label Supply Customers”

MediPharm Labs Launches New Sublingual Sprays for Sale via Medical Cannabis by Shoppers™ Under Agreement With Avicanna

— MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly-owned subsidiary, MediPharm Labs Inc., has launched and completed production of a new product format, sublingual sprays, as part of its multi-faceted strategic pharmaceutical manufacturingContinue reading “MediPharm Labs Launches New Sublingual Sprays for Sale via Medical Cannabis by Shoppers™ Under Agreement With Avicanna”